Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 4/20 | 0.41 |
| ▸ | CA2 | P00918 | 4/20 | 0.41 |
| ▸ | CA12 | O43570 | 3/20 | 0.41 |
| ▸ | CA9 | Q16790 | 3/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | STK17B | O94768 | 1/20 | 0.37 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.37 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | GFER | P55789 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15691937 | 1.00 | MEN1 (0.54) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL26084958 | 1.00 | MEN1 (0.54) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL5019057 | 0.89 | MEN1 (0.61) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL23690865 | 0.84 | MEN1 (0.56) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL17452213 | 0.84 | MEN1 (0.56) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL8194926 | 0.84 | MEN1 (0.56) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL751969 | 0.84 | MEN1 (0.56) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL22433494 | 0.84 | MEN1 (0.56) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL17144776 | 0.83 | MEN1 (0.51) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL17144126 | 0.83 | MEN1 (0.54) | MEN1GAAKMT2ATDP1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023192145-A1 | SYNTHESIS OF DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-10-05 | — | — | WO | disclosed |
| US-9873692-B2 | Quinolinone-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-01-23 | — | — | US | disclosed |
| US-20170334901-A1 | QUINOLINONE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-11-23 | — | — | US | disclosed |
| US-9630960-B2 | Quinolinone-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-04-25 | — | — | US | disclosed |
| US-20160376264-A1 | QUINOLINONE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-12-29 | — | — | US | disclosed |
| US-9353106-B2 | Quinolinone-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-05-31 | — | — | US | disclosed |
| US-20150291580-A1 | QUINOLINONE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-10-15 | — | — | US | disclosed |
| US-8962653-B2 | Quinolinone-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-02-24 | — | — | US | disclosed |
| US-20140163063-A1 | QUINOLINONE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| US-8575192-B2 | Quinolinone-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-7375114-B2 | Quinolinone-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE, INC. (US) | 2008-05-20 | — | — | US | disclosed |
| US-20080070923-A1 | Benzoimidazolone-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-03-20 | — | — | US | disclosed |
| US-7317022-B2 | Benzoimidazolone-carboxamide compounds as 5-HT4 receptors agonists | THERAVANCE, INC. (US) | 2008-01-08 | — | — | US | disclosed |
| US-20070281970-A1 | Quinolinone-Carboxamide Compounds as 5-Ht4 Receptor Agonists | ALFASIGMA S.P.A. (IT) | 2007-12-06 | — | — | US | disclosed |
| US-20070270457-A1 | Quinolinone-carboxamide compounds as 5-HT, receptor agonists | ALFASIGMA S.P.A. (IT) | 2007-11-22 | — | — | US | disclosed |
| EP-1735304-A1 | QUINOLINONE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | Theravance, Inc. (US) | 2006-12-27 | — | — | EP | disclosed |
| US-20060276482-A1 | Benzoimidazolone-carboxamide compounds as 5-HT4 receptors agonists | THERAVANCE, INC. | 2006-12-07 | — | — | US | disclosed |
| US-20060135764-A1 | Indazole-carboxamide compounds | THERAVANCE, INC. | 2006-06-22 | — | — | US | disclosed |
| WO-2005100350-A1 | QUINOLINONE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE, INC. (US) | 2005-10-27 | — | — | WO | disclosed |
| US-20050228014-A1 | Quinolinone-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE, INC. | 2005-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276482-A1 | Benzoimidazolone-carboxamide compounds as 5-HT4 receptors agonists | HTR4, HTR5A, HTR1A | MEN1 2147/4885GAA 3928/4885KMT2A 2365/4885 |
| US-20050228014-A1 | Quinolinone-carboxamide compounds as 5-HT4 receptor agonists | HTR4, HTR5A, HTR1A | MEN1 1587/4885GAA 3859/4885KMT2A 1511/4885 |
| US-20070270457-A1 | Quinolinone-carboxamide compounds as 5-HT, receptor agonists | HTR4, HTR5A, HTR1A | MEN1 1392/4885GAA 3748/4885KMT2A 1436/4885 |
| US-20080070923-A1 | Benzoimidazolone-carboxamide compounds as 5-HT4 receptor agonists | HTR4, HTR5A, HTR1A | MEN1 1999/4885GAA 3864/4885KMT2A 2371/4885 |
| US-20160376264-A1 | QUINOLINONE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | HTR4, HTR5A, HTR1A | MEN1 1587/4885GAA 3859/4885KMT2A 1511/4885 |
| US-20150291580-A1 | QUINOLINONE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | HTR4, HTR5A, HTR1A | MEN1 1587/4885GAA 3859/4885KMT2A 1511/4885 |
| US-20170334901-A1 | QUINOLINONE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | HTR4, HTR5A, HTR1A | MEN1 1587/4885GAA 3859/4885KMT2A 1511/4885 |
| US-20060135764-A1 | Indazole-carboxamide compounds | HTR4, HTR5A, HTR3B | MEN1 2636/4885GAA 3450/4885KMT2A 2426/4885 |
| US-20070281970-A1 | Quinolinone-Carboxamide Compounds as 5-Ht4 Receptor Agonists | HTR4, HTR7, HTR3C | MEN1 1341/4885GAA 4773/4885KMT2A 2280/4885 |
| US-20140163063-A1 | QUINOLINONE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | HTR4, HTR5A, HTR1A | MEN1 1587/4885GAA 3859/4885KMT2A 1511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.